MedTrace Logo

QUANTRA® References Range Protocol in Pregnancy and Postpartum

NCT04753671 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2025-12-26

No results posted yet for this study

Summary

Postpartum hemorrhage (PPH) remains the leading cause of maternal death. PPH associated coagulopathy varies and their treatments (tranexamic acid, fibrinogen concentrates,plasma, platelets need to be targeted and administrated early. Point of care hemostasis devices are helpful to develop this strategy. Quantra® (STAGO BIOCARE) use an innovative method to detect the clot formation. Pregnancy and non-hemorrhagic postpartum reference ranges are missing. The objective of this study is to establish these norms needed to elaborate thereafter the thresholds to be targeted in PPH conditions.

Conditions

  • Pregnancy Postpartum

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Anne-Sophie DUCLOY-BOUTHORS, MD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2022-11-07
Completion
2022-11-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753671 on ClinicalTrials.gov